Agappe Diagnostics ties up with Hitachi Chemical Company
The instrument enables early detection of kidney malfunctioning, cardiac problems and osteoporosis. It can also support detection of prostate cancer and TB.
Thomas John, managing director, Agappe, said the manufacture of the equipment would commence at Agappe’s manufacturing facility in Kochi in a year and it would help to bring down the costs of the tests by analysers.
The instrument provides ease in operation, at roughly one third cost per test compared to the conventional method analyzers. Affordable pricing would help rural penetration with medium and smaller labs also entering the platform of advanced testing. ``The aim is to provide everyone across the nation right result at right time for proper diagnosis and treatment,’’Thomas John said.
Tsuyoshi Uchida deputy general manager, medical business unit, Hitachi Chemical Co., Ltd. said with the instrument there is a special advantage of automatic retrieval of calibration due to pre-calibration, where the chances of errors are almost zero.
The instrument enables early detection of kidney malfunctioning, cardiac problems and osteoporosis. It can also support detection of prostate cancer and TB.
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions